Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
Above average. ANI Pharmaceuticals, Inc. scores higher than 68% of the 1,794 companies Ryufin scores.
Carried by valuation and return on new capital, held back by return on capital and capital allocation.
Healthcare median 28 · all companies 57
The biggest move was up 27 points from 2023 to 2025, mostly return on new capital.
26% of the score, 30% here after data gaps
ANI Pharmaceuticals, Inc. is valued at 8.1x its operating profit before acquisition amortisation (EBITA), including debt: a low multiple.
18% of the score, 20% here after data gaps
Over 7 years the business earned 1.5% a year after tax on the capital it uses.
16% of the score, 18% here after data gaps
For every dollar of operating profit earned over 6 years, yearly profit grew by 121 cents. New capital earned 17%, and 722% of profit went back into the business.
14% of the score, 16% here after data gaps
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
Taken out: its 12% is shared by the others
Margins have been too thin to measure a cycle against.
8% of the score, 9% here after data gaps
What the debt weighs against the profit that has to carry it.
6% of the score, 7% here after data gaps
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. For ANIP, cycle position could not be measured from the filings, so it is taken out and the remaining weights scale up.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.
Ranks #8 of 29 by RyuScore